Pharma Commons
  • Home
  • About
  • Company List
  • Contact

Astellas

Pfizer, Astellas’ Xtandi OK’d for second prostate cancer variant

July 16, 2018 BIO SmartBrief Astellas

The FDA approved Pfizer and Astellas Pharma’s Xtandi, or enzalutamide, as a treatment for men with non-metastatic castration- -More- …

Continue reading


With FDA nod, Pfizer and Astellas’ Xtandi gets its shot at blockbuster sales boost

July 16, 2018 FiercePharma: Pharma Astellas

Pfizer and Astellas have their chance to bring Xtandi to prostate cancer patients before their disease has spread. But it’ll be a mano a mano with Johnson & Johnson, whose rival drug Erleada…

Continue reading


FDA priority review status granted to Astellas’ AML drug

May 30, 2018 BIO SmartBrief Astellas

Astellas Pharma’s gilteritinib, which is being developed as a treatment for adult patients with relapsed/refractory FLT3-posi -More- …

Continue reading


Priority review for Astellas’ AML drug

May 30, 2018 PharmaTimes: News RSS Astellas

Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.

Continue reading


Posts navigation

Older posts

Receive a daily news digest

Enter your email address:

Search the archive

Search for:

Company list

Browse by tags

Abbott abbott laboratories Amgen astrazeneca astrazeneca plc Bayer biogen idec boehringer ingelheim breast cancer bristol myers bristol myers squibb bristol myers squibb company cancer drug diabetes drug eli lilly eli lilly and company food and drug administration genepool gilead sciences gilead sciences inc glaxosmithkline glaxosmithkline plc gsk latest biotech news Lilly lilly and company london reuters Merck merck kgaa merck serono Myers Nordisk Novartis novartis ag novo nordisk pfizer pfizer inc Pharma PLC PRNewswire reuters Roche roche holding ag rsquo sanofi
dazzling Theme by Colorlib Powered by WordPress